exposed-hypodermic-needle-300x200-5715270The makers of the anti-addiction drug Vivitrol – whose controversial nationwide lobbying campaign was spotlighted by the New York Times last week – appear to be getting results in Albany.

A bill advancing in the Assembly would bar insurers from requiring prior authorization for certain drugs used in the treatment of opioid addiction, including “long-acting injectable naltrexone.” Vivitrol, manufactured by Alkermes, is the brand name for the injectable form of naltrexone.

The legislation also applies to methadone and buprenorphine, anti-addiction drugs that are available in generic form. The reference to “long-lasting” and “injectable” would appear to leave out generic versions of naltrexone.

Under prior authorization, health plans will not cover certain medications and procedures unless the treating physician gets their approval in advance. Plans often apply the rule to brand-name drugs as a way of controlling costs when less-expensive alternatives are available. Under the bill, however, health plans could not challenge a doctor’s decision to prescribe Vivitrol, which typically costs about $1,000 for a shot that lasts one month.

The Assembly bill, sponsored by Dan Quart of Manhattan, was advanced by the Insurance Committee on Monday and by the Codes Committee on Tuesday. It is currently awaiting action by the Rules Committee, a last stop before a vote by the full Assembly.

A companion bill in the Senate was introduced by George Amedore of Rotterdam last week. It also awaits action by the Rules Committee.

As reported by the Times, the makers of Vivitrol have gained market share by portraying it as preferable to drugs like buprenorphine and methadone, which are themselves opioids used in controlled doses to manage cravings. Vivitrol, on the other hand, is designed to block opioid receptors in the brain, which prevents users from getting high and, in theory, helps break their addiction.

Some experts told the Times, however, that there is not yet scientific evidence to document that Vivitrol is as effective as competing treatments.

Despite those doubts, 39 states have moved to cover Vivitrol through their Medicaid program, up from 15 five years ago, the Times said. New York lawmakers joined the trend in 2016, as part of a package negotiated by Governor Andrew Cuomo in response to the opioid abuse epidemic.

Over the past year, under pressure from Attorney General Eric Schneiderman, two major insurers – Cigna and Anthem – have agreed to end prior authorization for medication-assisted treatment drugs. Those agreements, signed in October and January, cover the broad range of available medications, including both injectable and oral naltrexone

The current bill – one of 11 opioid-related measures that Cuomo is reportedly supporting this year – would expand the ban on prior authorization for certain medication-assisted treatment drugs to a portion of New York’s commercial health plans, primarily those sold to individuals and small groups. Most large groups are exempt from state regulation under federal law.

If enacted, the legislation would add to the dozens of mandates that the state already imposes on health plans, adding substantially to New York’s high premiums. Many go beyond the recommendations of medical experts, and none is subjected to independent cost-benefit analysis. The Amedore-Quart bill is one of at least 100 proposals currently pending in the Legislature, 26 of which have majority-party sponsors in both houses.


About the Author

Bill Hammond

As the Empire Center’s senior fellow for health policy, Bill Hammond tracks fast-moving developments in New York’s massive health care industry, with a focus on how decisions made in Albany and Washington affect the well-being of patients, providers, taxpayers and the state’s economy.

Read more by Bill Hammond

You may also like

How a Medicaid Program To Improve Nursing Home Care Ended Up Paying for Union Benefits

New York State's budget-making process sometimes works like a closed loop, as interest groups on the receiving end of state spending reinvest a portion of their proceeds to lobby Albany for still more money. Read More

Despite Lingering Shortages, New York’s Health-Care Workforce Is Bigger Than Ever

The state's health-care workforce is recovering unevenly from the pandemic, with persistently lower employment levels in some areas and robust growth in others. This mixed pattern c Read More

The Wacky Math of New York’s Essential Plan

Thanks to an absurdly wasteful federal law, New York's Essential Plan is expected to continue running billion-dollar surpluses even as state officials more than double its spending over the next several years. Read More

In a Tight Budget Year, New York’s Hospital Lobby Shoots for the Moon

As Governor Hochul calls for spending restraint next year, influential hospital lobbyists are pushing what could be the costliest budget request ever floated in Albany. In a , the G Read More

Putting the Mission in Hochul’s Health Commission

Last week Governor Hochul answered one big question about her Commission on the Future of Health Care – the names of its members – but left a fundamental mystery unresolved:  W Read More

Medicaid Drug ‘Carve-Out’ Led to Double Payments

The state's Medicaid program has effectively been double-paying for prescription drugs for the past six months due to a glitch with the roll-out of its pharmacy "carve-out." Since A Read More

DFS Pulls Back Draft Regulations That Would Have Added a Fee for Prescriptions

A package of proposed regulations that included a $10.18 fee for filling most drug prescriptions was withdrawn Tuesday by the Department of Financial Services in the face of broad opposition. Read More

Hochul’s Promised Health Care Commission Has Yet To Be Appointed

A health-care commission that is supposed to be helping the state control soaring Medicaid costs – which Governor Hochul promised in January and described as "under way" last month – appears not to exist. Thre Read More